Ticker

MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy…

Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the appointment of Zachary Smith as Vice President of its…

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders MIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company").

Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment

Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment MELVILLE, N. Y. , May 26, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on…